229 related articles for article (PubMed ID: 20691511)
1. Three-dimensional quantitative structure-activity relationship CoMSIA/CoMFA and LeapFrog studies on novel series of bicyclo [4.1.0] heptanes derivatives as melanin-concentrating hormone receptor R1 antagonists.
Morales-Bayuelo A; Ayazo H; Vivas-Reyes R
Eur J Med Chem; 2010 Oct; 45(10):4509-22. PubMed ID: 20691511
[TBL] [Abstract][Full Text] [Related]
2. Three-dimensional quantitative structure-activity relationship studies on novel series of benzotriazine based compounds acting as Src inhibitors using CoMFA and CoMSIA.
Gueto C; Ruiz JL; Torres JE; Méndez J; Vivas-Reyes R
Bioorg Med Chem; 2008 Mar; 16(5):2439-47. PubMed ID: 18065233
[TBL] [Abstract][Full Text] [Related]
3. Bicyclic[4.1.0]heptanes as phenyl replacements for melanin concentrating hormone receptor antagonists.
Xu R; Li S; Paruchova J; McBriar MD; Guzik H; Palani A; Clader JW; Cox K; Greenlee WJ; Hawes BE; Kowalski TJ; O'Neill K; Spar BD; Weig B; Weston DJ
Bioorg Med Chem; 2006 May; 14(10):3285-99. PubMed ID: 16442800
[TBL] [Abstract][Full Text] [Related]
4. 3D-QSAR CoMFA/CoMSIA studies on 5-aryl-2,2-dialkyl-4-phenyl-3(2H)-furanone derivatives, as selective COX-2 inhibitors.
Puntambekar DS; Giridhar R; Yadav MR
Acta Pharm; 2006 Jun; 56(2):157-74. PubMed ID: 16613723
[TBL] [Abstract][Full Text] [Related]
5. 3D-QSAR studies on CCR2B receptor antagonists: Insight into the structural requirements of (R)-3-aminopyrrolidine series of molecules based on CoMFA/CoMSIA models.
Gade S; Mahmood S
J Pharm Bioallied Sci; 2012 Apr; 4(2):123-33. PubMed ID: 22557923
[TBL] [Abstract][Full Text] [Related]
6. Development of predictive 3D-QSAR CoMFA and CoMSIA models for beta-aminohydroxamic acid-derived tumor necrosis factor-alpha converting enzyme inhibitors.
Murumkar PR; Gupta SD; Zambre VP; Giridhar R; Yadav MR
Chem Biol Drug Des; 2009 Jan; 73(1):97-107. PubMed ID: 19152638
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of novel bicyclo[4.1.0]heptane and bicyclo[3.1.0]hexane derivatives as melanin-concentrating hormone receptor R1 antagonists.
Su J; Tang H; McKittrick BA; Gu H; Guo T; Qian G; Burnett DA; Clader JW; Greenlee WJ; Hawes BE; O'neill K; Spar B; Weig B; Kowalski T; Sorota S
Bioorg Med Chem Lett; 2007 Sep; 17(17):4845-50. PubMed ID: 17604169
[TBL] [Abstract][Full Text] [Related]
8. CoMFA and CoMSIA 3D QSAR analysis on N1-arylsulfonylindole compounds as 5-HT6 antagonists.
Doddareddy MR; Cho YS; Koh HY; Pae AN
Bioorg Med Chem; 2004 Aug; 12(15):3977-85. PubMed ID: 15246074
[TBL] [Abstract][Full Text] [Related]
9. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
10. CoMFA and CoMSIA 3D-QSAR analysis of diaryloxy-methano-phenanthrene derivatives as anti-tubercular agents.
Shagufta ; Kumar A; Panda G; Siddiqi MI
J Mol Model; 2007 Jan; 13(1):99-109. PubMed ID: 16858589
[TBL] [Abstract][Full Text] [Related]
11. Computational Analysis of CRTh2 receptor antagonist: A Ligand-based CoMFA and CoMSIA approach.
Babu S; Sohn H; Madhavan T
Comput Biol Chem; 2015 Jun; 56():109-21. PubMed ID: 25935115
[TBL] [Abstract][Full Text] [Related]
12. CoMFA and CoMSIA 3D-QSAR studies on quionolone caroxylic acid derivatives inhibitors of HIV-1 integrase.
Lu P; Wei X; Zhang R
Eur J Med Chem; 2010 Aug; 45(8):3413-9. PubMed ID: 20488589
[TBL] [Abstract][Full Text] [Related]
13. 3D QSAR studies on T-type calcium channel blockers using CoMFA and CoMSIA.
Doddareddy MR; Jung HK; Cha JH; Cho YS; Koh HY; Chang MH; Pae AN
Bioorg Med Chem; 2004 Apr; 12(7):1613-21. PubMed ID: 15028254
[TBL] [Abstract][Full Text] [Related]
14. Comparative molecular field analysis and comparative molecular similarity indices analysis of human thymidine kinase 1 substrates.
Bandyopadhyaya AK; Johnsamuel J; Al-Madhoun AS; Eriksson S; Tjarks W
Bioorg Med Chem; 2005 Mar; 13(5):1681-9. PubMed ID: 15698786
[TBL] [Abstract][Full Text] [Related]
15. 3D-QSAR CoMFA/CoMSIA studies on Urokinase plasminogen activator (uPA) inhibitors: a strategic design in novel anticancer agents.
Bhongade BA; Gadad AK
Bioorg Med Chem; 2004 May; 12(10):2797-805. PubMed ID: 15110861
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR comparative molecular field analysis on opioid receptor antagonists: pooling data from different studies.
Peng Y; Keenan SM; Zhang Q; Kholodovych V; Welsh WJ
J Med Chem; 2005 Mar; 48(5):1620-9. PubMed ID: 15743203
[TBL] [Abstract][Full Text] [Related]
17. Profiling the interaction mechanism of quinoline/quinazoline derivatives as MCHR1 antagonists: an in silico method.
Wu M; Li Y; Fu X; Wang J; Zhang S; Yang L
Int J Mol Sci; 2014 Sep; 15(9):15475-502. PubMed ID: 25257526
[TBL] [Abstract][Full Text] [Related]
18. Ligand-based CoMFA and CoMSIA studies on chromone derivatives as radical scavengers.
Phosrithong N; Ungwitayatorn J
Bioorg Chem; 2013 Aug; 49():9-15. PubMed ID: 23838011
[TBL] [Abstract][Full Text] [Related]
19. CoMFA and CoMSIA 3D-QSAR analysis of DMDP derivatives as anti-cancer agents.
Srivastava V; Kumar A; Mishra BN; Siddiqi MI
Bioinformation; 2008 Jun; 2(9):384-91. PubMed ID: 18795111
[TBL] [Abstract][Full Text] [Related]
20. CoMFA and CoMSIA studies of angiotensin (AT1) receptor antagonists.
Datar P; Desai P; Coutinho E; Iyer K
J Mol Model; 2002 Oct; 8(10):290-301. PubMed ID: 12483229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
